REPUBLIC OF LEBANON
MINISTRY OF PUBLIC HEALTH

List of Requirements for the registration of Biosimilar products according to CTD format

List of Requirements for the registration of Biosimilar products according to CTD format

Module 1: Administrative information

1.1 Cover letter/application form/proposed summary of product characteristics/labeling and package insert leaflet.
1.2 Trade name
1.3 Generic name
1.4 Expiry date
1.5 Other trade names of the similar product
1.6 Pharmaceutical form
1.7 Name of manufacturing company
1.8 Name of active substance manufacturer (if different from above)
1.9 Agent in Lebanon: Name and Address
1.10 Marketing status at country of origin and other countries
1.11 Reference medicinal product (RMP) – The innovator Name, Approval at EMA/FDA
1.12: Labeling product information

Module 2: Common technical document summaries

2.1. Table of contents of Modules 2 – 5.
2.2. Introduction.
2.3. Quality overall summary.
2.4. Pre-clinical overview:
2.5. Clinical overview.
2.6. Pre-clinical summary.
2.6.1. Pharmacology written summary.
2.6.2. Pharmacology tabulated summary.
2.6.3. Pharmacokinetics written summary.
2.6.4. Pharmacokinetics tabulated summary.
2.6.5. Toxicology written summary.
2.6.6. Toxicology tabulated summary.
2.7. Clinical summary:
2.7.1. Summary of biopharmaceutical studies and associated analytical methods.
2.7.2. Summary of clinical pharmacology studies.
2.7.3. Summary of clinical efficacy.
2.7.4. Summary of clinical safety.
2.7.5. Literature references.
2.7.6 Synopses of individual studies.

Module 3: Quality

3.2.S. Active substance(s).

3.2.S.1. General information
3.2.S.1.2. Structure
3.2.S.1.3. General properties

3.2.S.2. Manufacture of active substance(-s):
3.2.S.2.1. Manufacturer(s).
3.2.S.2.2. Description of manufacturing process and process controls.
S.2.S.2.3. Control of materials
3.2.S.2.4. Controls of critical steps and intermediates.
3.2.S.2.4.1 Critical steps
3.2.S.2.4.2 Intermediates
3.2.S.2.5. Process validation and/or evaluation.
3.2.S.2.6. Manufacturing process development.
3.2.S.3. Characterization of active substance(-s).
3.2.S.3.1. Elucidation of structure and other characteristics.
3.2.S.3.2. Impurities.
3.2.S.4. Control of active substance(s).
3.2.S.4.1. Specification.
3.2.S.4.2. Analytical procedures.
3.2.S.4.3. Validation of analytical procedures.
3.2.S.4.4. Batch analyses
3.2.S.4.5. Justification of specification.
3.2.S.5. Reference standards or materials.
3.2.S.6. Container/closure system.
3.2.S.7. Stability
3.2.S.7.1. Stability summary and conclusions.
3.2. S.7.2. Post-approval stability protocol and stability commitment.
3.2. S.7.3. Stability data

3.2.P. Finished medicinal product

3.2.P.1. Description and composition of the finished medicinal product
3.2.P.2. Pharmaceutical development
3.2.P.2.1. Composition of the finished medicinal product
3.2.P.2.1.1. Active substance(s).
3.2.P.2.1.2. Excipients.
3.2.P.2.2. Medicinal product.
3.2.P.2.2.1. Formulation development.
3.2.P.2.2.2. Overages.
3.2.P.2.2.3. Physicochemical and biological properties.
3.2.3 Manufacturing process development
3.2.P.2.4. Container/closure system.
3.2.P.2.5. Microbiological attributes.
3.2.P.2.6. Compatibility
3.2.P.3. Manufacture of the finished medicinal product
3.2.P.3.1. Manufacturer(s)
3.2.P.3.2. Batch formula
3.2.P.3.3. Description of manufacturing process and process controls.
3.2.P.3.4. Controls of critical steps and intermediates.
3.2.P.3.5. Process validation and/or evaluation.
3.2.P.4. Control of excipients
3.2.P.4.1. Specifications
3.2.P.4.2. Analytical procedures.
3.2.P.4.3. Validation of analytical procedures.
3.2.P.4.4. Justification of specifications.

3.2.P.4.5. Excipients of human or animal origin.
3.2.P.4.6. Novel excipients.
3.2.P.5. Control of finished medicinal product
3.2.P.5.2. Analytical procedures.
3.2.P.5.3. Validation of analytical procedures.
3.2.P.5.4. Batch analyses.
3.2.P.5.5. Characterization of impurities.
3.2.P.5.6. Justification of specification(s).
3.2.P.6. Reference standards and materials.
3.2.P.7.Container closure system.
3.2.P.8. Stability
3.2.P.8.1. Stability summary and conclusion
3.2.P.8.2. Post-approval stability protocol and stability commitment
3.2.P.8.3. Stability data
3.2.A. Appendices:
3.2.A.1. Facilities and equipment.
3.2.A.2. Adventitious agents safety evaluation.
3.2.A.2.1 For non-viral adventitious agents
3.2.A.2.2 For viral adventitious agents
3.3. Literature references.

Module 4: Safety (nonclinical study reports)

4.2.1. Pharmacology
4.2.1.1. Primary pharmacodynamics
4.2.2. Pharmacokinetics:
4.2.1.1. Primary pharmacodynamics
4.2.3. Toxicology
4.2.3.1. Single-dose toxicity.
4.2.3.2. Repeated dose toxicity.
4.2.3.6. Local tolerance
4.2.3.7. Other toxicity studies.
Immunogenicity profile

Module 5: Efficacy (clinical study reports)

Protocol
Recruitment details
Informed consent document(s)
Clinical trial site information
Eligibility criteria
5.3. Clinical study reports:
5.3.1. Reports of biopharmaceutical studies.
5.3.2. Reports of studies pertinent to pharmacokinetics using human biomaterials
5.3.3. Reports of human pharmacokinetic studies.
5.3.4. Reports of human pharmacodynamic studies
5.3.5. Reports of efficacy and safety studies.
Statistics
5.3.6. Reports of post-registration experience.

Testing of immunogenicity
5.4. Literature references.

6. Pharmacovigilance plan

6.1 Pharmacovigilance plan (track and trace)
6.2 Recall plan
6.3 Plan for adverse reactions (ADR) reports
6.4 Plan to ensure quality of the product (defect, final formulation package)
6.5 Bar-coding method
6.6 Post approval stability protocol and stability commitments